Accelerate Diagnostics, Inc. (NASDAQ:AXDX - Get Free Report) CEO Jack Phillips sold 26,735 shares of the company's stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $0.78, for a total transaction of $20,853.30. Following the sale, the chief executive officer now directly owns 162,919 shares of the company's stock, valued at approximately $127,076.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Jack Phillips also recently made the following trade(s):
- On Friday, April 12th, Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70.
- On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
- On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.
Accelerate Diagnostics Trading Up 4.5 %
Shares of AXDX stock opened at $0.77 on Friday. The company's 50-day moving average price is $1.00 and its 200-day moving average price is $3.20. The stock has a market cap of $16.68 million, a price-to-earnings ratio of -0.16 and a beta of 0.52. Accelerate Diagnostics, Inc. has a twelve month low of $0.73 and a twelve month high of $11.90.
Analyst Ratings Changes
Elon’s New Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of equities research analysts have recently issued reports on AXDX shares. William Blair reaffirmed an "outperform" rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd. Craig Hallum dropped their target price on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a "hold" rating for the company in a report on Monday, April 1st. Finally, StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Friday, April 12th. They set a "hold" rating for the company.
Get Our Latest Report on AXDX
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Sonora Investment Management Group LLC acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at about $63,000. Swiss National Bank boosted its position in shares of Accelerate Diagnostics by 19.0% during the 1st quarter. Swiss National Bank now owns 85,300 shares of the medical research company's stock valued at $123,000 after acquiring an additional 13,600 shares during the last quarter. Tejara Capital Ltd acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter valued at about $78,000. Virtu Financial LLC boosted its position in shares of Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company's stock valued at $25,000 after acquiring an additional 17,461 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of Accelerate Diagnostics during the 1st quarter valued at about $27,000. Institutional investors and hedge funds own 17.14% of the company's stock.
About Accelerate Diagnostics
(
Get Free Report)
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
